SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/12/19 Biolase, Inc 10-Q 9/30/19 86:10M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 792K 7: EX-4.8 Instrument Defining the Rights of Security Holders HTML 95K 2: EX-10.5 Material Contract HTML 55K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 32K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 32K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 6: EX-32.2 Certification -- §906 - SOA'02 HTML 27K 54: R1 Document and Entity Information HTML 78K 32: R2 Consolidated Balance Sheets (Unaudited) HTML 111K 39: R3 Consolidated Balance Sheets (Unaudited) HTML 47K (Parenthetical) 83: R4 Consolidated Statements Of Operations And HTML 97K Comprehensive Loss (Unaudited) 52: R5 Consolidated Statements of Stockholders' (Deficit) HTML 58K Equity (Unaudited) 31: R6 Consolidated Statements Of Cash Flows (Unaudited) HTML 134K 38: R7 Description of Business and Basis of Presentation HTML 42K 81: R8 Summary of Significant Accounting Policies HTML 40K 55: R9 Revenue Recognition HTML 215K 48: R10 Stockholders' (Deficit) Equity HTML 300K 21: R11 Inventory HTML 46K 64: R12 Property, Plant, and Equipment HTML 67K 73: R13 Intangible Assets and Goodwill HTML 29K 47: R14 Accrued Liabilities HTML 117K 20: R15 Debt HTML 103K 63: R16 Leases HTML 74K 72: R17 Commitments and Contingencies HTML 34K 46: R18 Segment Information HTML 75K 22: R19 Concentrations HTML 114K 50: R20 Income Taxes HTML 31K 79: R21 Subsequent Events HTML 36K 34: R22 Summary of Significant Accounting Policies HTML 77K (Policies) 24: R23 Revenue Recognition (Tables) HTML 296K 49: R24 Stockholders' (Deficit) Equity (Tables) HTML 304K 78: R25 Inventory (Tables) HTML 47K 33: R26 Property, Plant, and Equipment (Tables) HTML 66K 23: R27 Accrued Liabilities (Tables) HTML 118K 51: R28 Debt (Tables) HTML 79K 77: R29 Leases (Tables) HTML 75K 74: R30 Segment Information (Tables) HTML 76K 66: R31 Concentrations (Tables) HTML 166K 18: R32 Description of Business and Basis of Presentation HTML 69K - Additional Information (Detail) 44: R33 Summary of Significant Accounting Policies - HTML 36K Additional Information (Detail) 75: R34 Revenue Recognition - Additional Information HTML 38K (Detail) 67: R35 Summary of Opening and Closing Balances of HTML 36K Contract Liabilities (Detail) 19: R36 Summary of Disaggregation of Revenues Related to HTML 32K Geographic Areas (Detail) 45: R37 Summary of Revenues Disaggregated by Timing of HTML 33K Goods and Services Transferred (Detail) 76: R38 Summary of Sales by End Market (Detail) HTML 33K 65: R39 Summary of Percentages of Sales by Product line HTML 40K (Detail) 80: R40 Stockholders' (Deficit) Equity - Additional HTML 84K Information (Detail) 56: R41 Classification of Compensation Expense Associated HTML 38K with Share-Based Payments (Detail) 29: R42 Assumptions Used in Estimating Fair Value of Stock HTML 34K Options Granted (Detail) 40: R43 Summary of Option Activity (Detail) HTML 65K 82: R44 Summary of Unvested Stock Option Activity (Detail) HTML 47K 57: R45 Cash Proceeds Along with Fair Value Disclosures HTML 33K Related to Grants, Exercises and Vested Options (Detail) 30: R46 Summary of Unvested Restricted Stock Units HTML 50K (Detail) 41: R47 Summary of Warrant Activity (Detail) HTML 43K 84: R48 Components of Inventory (Detail) HTML 35K 53: R49 Inventory - Additional Information (Detail) HTML 28K 61: R50 Summary of Property, Plant, and Equipment (Detail) HTML 49K 70: R51 Property, Plant, and Equipment - Additional HTML 28K Information (Detail) 43: R52 Intangible Assets and Goodwill - Additional HTML 34K Information (Detail) 17: R53 Components of Accrued Liabilities (Detail) HTML 52K 60: R54 Changes in Initial Product Warranty Accrual and HTML 41K Expenses Under Initial and Extended Warranties (Detail) 69: R55 Accrued Liabilities - Additional Information HTML 33K (Detail) 42: R56 Debt - Summary of Principal Outstanding and HTML 33K Unamortized Discount (Detail) 16: R57 Debt - Additional Information (Detail) HTML 209K 62: R58 Debt - Summary of Future Minimum Principal and HTML 49K Interest Payments (Detail) 68: R59 Leases - Additional Information (Detail) HTML 59K 37: R60 Leases - Information related to Right-of-use HTML 34K Assets and Liabilities (Detail) 27: R61 Leases - Schedule of Maturities of Lease HTML 39K Liabilities (Detail) 59: R62 Leases - Future Minimum Rental Commitments Under HTML 35K Lease Agreements (Detail) 86: R63 Commitments and Contingencies - Additional HTML 56K Information (Detail) 36: R64 Segment Information - Additional Information HTML 39K (Detail) 26: R65 Summary of Net Revenue by Geographic Location HTML 32K (Detail) 58: R66 Summary of Property, Plant and Equipment by HTML 33K Geographic Location (Detail) 85: R67 Concentrations - Summary of Net Revenue from HTML 51K Various Products (Detail) 35: R68 Concentrations - Additional Information (Detail) HTML 41K 28: R69 Income Taxes - Additional Information (Detail) HTML 37K 15: R70 Subsequent Events - Additional Information HTML 88K (Detail) 14: XML IDEA XML File -- Filing Summary XML 153K 71: EXCEL IDEA Workbook of Financial Reports XLSX 91K 8: EX-101.INS XBRL Instance -- biol-20190930 XML 2.79M 10: EX-101.CAL XBRL Calculations -- biol-20190930_cal XML 170K 11: EX-101.DEF XBRL Definitions -- biol-20190930_def XML 583K 12: EX-101.LAB XBRL Labels -- biol-20190930_lab XML 1.39M 13: EX-101.PRE XBRL Presentations -- biol-20190930_pre XML 1.06M 9: EX-101.SCH XBRL Schema -- biol-20190930 XSD 215K 25: ZIP XBRL Zipped Folder -- 0001564590-19-042402-xbrl Zip 178K
Exhibit 32.2
CERTIFICATION OF THE CHIEF financial OFFICER
PURSUANT TO 18 U.S.C. § 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BIOLASE, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2019 (the “Report”), I, John R. Beaver, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 8, 2019 |
|
By: |
/s/ JOHN R. BEAVER |
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer |
|
|
|
(Principal Financial Officer and Principal Accounting Officer) |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 11/12/19 | |||
Filed on: | 11/8/19 | |||
For Period end: | 9/30/19 | 8-K | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/03/23 Biolase, Inc. S-1/A 6:1M Donnelley … Solutions/FA 12/12/22 Biolase, Inc. S-1/A 7:1.1M Donnelley … Solutions/FA 11/22/22 Biolase, Inc. S-1 3:655K Donnelley … Solutions/FA 3/17/22 Biolase, Inc. 10-K 12/31/21 88:18M Donnelley … Solutions/FA 11/10/21 Biolase, Inc. 10-Q 9/30/21 84:13M Donnelley … Solutions/FA 8/13/21 Biolase, Inc. 10-Q 6/30/21 80:12M Donnelley … Solutions/FA 5/13/21 Biolase, Inc. 10-Q 3/31/21 81:9.4M Donnelley … Solutions/FA 3/31/21 Biolase, Inc. 10-K 12/31/20 88:15M ActiveDisclosure/FA 12/08/20 Biolase, Inc. S-1/A 3:585K Donnelley … Solutions/FA 11/13/20 Biolase, Inc. 10-Q 9/30/20 81:11M ActiveDisclosure/FA 8/14/20 Biolase, Inc. 10-Q 6/30/20 89:12M ActiveDisclosure/FA |